和誉-B（02256）披露lavengratinib治疗软骨发育不全II期试验取得积极初步疗效

公告速递09-21

2026年9月21日，和誉-B（02256）发布自愿性公告，旗下全资子公司上海和誉生物医药科技有限公司正在开展的口服小分子FGFR2/3抑制剂lavengratinib（ABSK061）用于儿童软骨发育不全（Achondroplasia，ACH）的II期临床研究获得积极初步结果。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohunote.com/m/news/1190577329?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-09-21 08:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1190577329","market":"sh","top_or_hot":-1,"title":"和誉-B（02256）披露lavengratinib治疗软骨发育不全II期试验取得积极初步疗效","media":"公告速递","content":"<p>2026年9月21日，和誉-B（02256）发布自愿性公告，旗下全资子公司上海和誉生物医药科技有限公司正在开展的口服小分子FGFR2/3抑制剂lavengratinib（ABSK061）用于儿童软骨发育不全（Achondroplasia，ACH）的II期临床研究获得积极初步结果。</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>和誉-B（02256）披露lavengratinib治疗软骨发育不全II期试验取得积极初步疗效</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n和誉-B（02256）披露lavengratinib治疗软骨发育不全II期试验取得积极初步疗效\n</h2>\n\n<h4 class=\"meta\">\n\n2026-09-21 08:11 北京时间&nbsp;&nbsp;&nbsp;<strong>公告速递</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>2026年9月21日，和誉-B（02256）发布自愿性公告，旗下全资子公司上海和誉生物医药科技有限公司正在开展的口服小分子FGFR2/3抑制剂lavengratinib（ABSK061）用于儿童软骨发育不全（Achondroplasia，ACH）的II期临床研究获得积极初步结果。</p>\n\n<a href=\"\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02256","symbol_name":"和誉-B","start_time":0,"source_url":"","article_id":"1190577329","we_media_id":"1097772564","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1190577329","pubTimestamp":1789949518,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"公告速递","introduction":"港美股公告全覆盖","home_visible":1,"id":"1097772564","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"2026年9月21日，和誉-B（02256）发布自愿性公告，旗下全资子公司上海和誉生物医药科技有限公司正在开展的口服小分子FGFR2/3抑制剂lavengratinib（ABSK061）用于儿童软骨发育不全（Achondroplasia，ACH）的II期临床研究获得积极初步结果。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"02256":"和誉-B"},"translate_title":"Heyu-B (02256) disclosed positive preliminary results in a Phase II trial of lavengratinib for the treatment of achondroplasia.","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02256":1},"content_text":"2026年9月21日，和誉-B（02256）发布自愿性公告，旗下全资子公司上海和誉生物医药科技有限公司正在开展的口服小分子FGFR2/3抑制剂lavengratinib（ABSK061）用于儿童软骨发育不全（Achondroplasia，ACH）的II期临床研究获得积极初步结果。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1190577329","isCrawlerRequest":true}